Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs

Solomon, Daniel H.; Curtis, Jeffrey R.; Saag, Kenneth G.; Lii, Joyce; Chen, Lang; Harrold, Leslie R.; Herrinton, Lisa J.; Graham, David J.; Kowal, Mary K.; Kuriya, Bindee; Liu, Liyan; Griffin, Marie R.; Lewis, James D.; Rassen, Jeremy A.

doi:10.1016/j.amjmed.2013.02.016

Cited by 112Rheumatoid Arthritis Research and TherapiesAutoimmune and Inflammatory Disorders ResearchInflammatory mediators and NSAID effects

Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs

Open access

Solomon, Daniel H., Curtis, Jeffrey R., Saag, Kenneth G., Lii, Joyce, Chen, Lang, Harrold, Leslie R., Herrinton, Lisa J., Graham, David J. +6 more·2013·The American Journal of Medicine

DOI 10.1016/j.amjmed.2013.02.016PMC PMC4674813

Open this paper in CoChat — free account

Abstract

Background Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD).Methods Subjects with rheumatoid arthritis participating in several different US insurance programs between 1998 and 2007 who received methotrexate were eligible. Those who added a TNF-α blocking agent were compared with subjects who added a nbDMARD in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage. We examined the composite cardiovascular end point of myocardial infarction, stroke, or coronary re-vascularization after 6 months.Results We compared 8656 new users of a nbDMARD with 11,587 new users of a TNF-α blocking agent with similar baseline covariates. Incidence rates per 100 person-years for the composite cardiovascular end point were 3.05 (95% confidence interval [CI], 2.54-3.65) for nbDMARDs and 2.52 (95% CI, 2.12-2.98) for TNF-α blocking agents. The hazard ratio (HR) for the TNF-α blocking agent compared with nbDMARD carrying the first exposure forward was 0.80 (95%, CI 0.62-1.04), while the HR for the as-treated analysis was 0.71 (95% CI, 0.52-0.97). The potential cardiovascular benefit of TNF-α blocking agents was strongest among individuals ≥65 years of age (HR 0.52; 95% CI, 0.34 -0.77; P for interaction = 0.075).Conclusion Among subjects with rheumatoid arthritis, TNF-α blocking agents may be associated with a reduced risk of cardiovascular events compared with an nbDMARD. Randomized controlled clinical trials should be considered to test this hypothesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.amjmed.2013.02.016

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Treatment with TNF inhibitors in rheumatoid arthritis is associated with a decreased risk of cardiovascular events.
“treatment with TNF inhibitors in rheumatoid arthritis, an overt inflammatory disease, is associated with a decreased risk of cardiovascular events”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [184]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241 · see citing works
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724 · see citing works
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965 · see citing works
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504 · see citing works
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641 · see citing works
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,486 · see citing works
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · see citing works
Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta‐analysis of observational studies
Aviña-Zubieta, J. A., Choi, H. K., Sadatsafavi, M., Etminan, M., Esdaile, J. M., & Lacaille, D. V. (2008) · Arthritis Care & Research · doi:10.1002/art.24092 · Cited by 1,461 · see citing works
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432 · see citing works
Rheumatoid arthritis
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,250 · see citing works
Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis
Solomon, D. H., Karlson, E. W., Rimm, E. B., Cannuscio, C. C., Mandl, L. A., Manson, J. E., Stampfer, M. J., & Curhan, G. C. (2003) · Circulation · doi:10.1161/01.cir.0000054612.26458.b2 · Cited by 1,240 · see citing works
Self-citation
Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study
Cesari, M., Penninx, B. W. J. H., Newman, A. B., Kritchevsky, S. B., Nicklas, B. J., Sutton-Tyrrell, K., Rubin, S. M., Ding, J., Simonsick, E. M., Harris, T. B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000097109.90783.fc · Cited by 978 · see citing works
Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction
Ridker, P. M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.101.18.2149 · Cited by 934 · see citing works
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799 · see citing works
Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations
Austin, P. C. (2009) · Biometrical Journal · doi:10.1002/bimj.200810488 · Cited by 769 · see citing works
Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors
Birman-Deych, E., Waterman, A. D., Yan, Y., Nilasena, D. S., Radford, M. J., & Gage, B. F. (2005) · Medical Care · doi:10.1097/01.mlr.0000160417.39497.a9 · Cited by 723 · see citing works
Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-One Matching on the Propensity Score
Austin, P. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq224 · Cited by 670 · see citing works
Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis
Hürlimann, D., Forster, A., Noll, G., Enseleit, F., Chenevard, R., Distler, O., Béchir, M., Spieker, L. E., Neidhart, M., Michel, B. A., et al. (2002) · Circulation · doi:10.1161/01.cir.0000037521.71373.44 · Cited by 573 · see citing works
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
Dixon, W. G., Watson, K. D., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22809 · Cited by 557 · see citing works
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson, L., Turesson, C., Gülfe, A., Kapetanovic, M. C., Petersson, I. F., Saxne, T., & Geborek, P. (2005) · PubMed · Cited by 533 · see citing works
Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records
Kiyota, Y., Schneeweiß, S., Glynn, R. J., Cannuscio, C. C., Avorn, J., & Solomon, D. H. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.02.013 · Cited by 533 · see citing works
Self-citation
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Naranjo, A., Sokka, T., Descalzo, M. Á., Alén, J. C., Hørslev‐Petersen, K., Luukkainen, R., Combe, B. G., Burmester, G. R., Devlin, J., Ferraccioli, G., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2383 · Cited by 464 · see citing works
Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction
Kurrelmeyer, K. M., Michael, L. H., Baumgarten, G., Taffet, G. E., Peschon, J. J., Sivasubramanian, N., Entman, M. L., & Mann, D. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070036297 · Cited by 440 · see citing works
TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure
Kleinbongard, P., Heusch, G., & Schulz, R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.002 · Cited by 408 · see citing works
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
Greenberg, J. D., Kremer, J. M., Curtis, J. R., Hochberg, M. C., Reed, G., Tsao, P., Farkouh, M. E., Nasir, A., Setoguchi, S., & Solomon, D. H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.129916 · Cited by 350 · see citing works
Self-citation
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
Kitas, G. D., & Gabriel, S. E. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142133 · Cited by 320 · see citing works
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity
Solomon, D. H., Kremer, J. M., Curtis, J. R., Hochberg, M. C., Reed, G. W., Tsao, P., Farkouh, M. E., Setoguchi, S., & Greenberg, J. D. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.122226 · Cited by 297 · see citing works
Self-citation
Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III
Johnson, M. L., Crown, W., Martin, B. C., Dormuth, C. R., & Siebert, U. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00602.x · Cited by 285 · see citing works
Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis
del Rincón, I., Freeman, G. L., Haas, R. W., O’Leary, D. H., & Escalante, A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21397 · Cited by 244 · see citing works
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Carmona, L., Descalzo, M. Á., Pérez-Pampín, E. M., Ruiz-Montesinos, D., Erra, A., Cobo‐Ibáñez, T., & Gómez-Reino, J. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067660 · Cited by 231 · see citing works
Validation of rheumatoid arthritis diagnoses in health care utilization data
Kim, S. C., Servi, A. D., Polinski, J. M., Mogun, H., Weinblatt, M. E., Katz, J. N., & Solomon, D. H. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3260 · Cited by 229 · see citing works
Self-citation
Developments in Post-marketing Comparative Effectiveness Research
Schneeweiß, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100249 · Cited by 199 · see citing works
Antirheumatic drug use and the risk of acute myocardial infarction
Suissa, S., Bernatsky, S., & Hudson, M. (2006) · Arthritis Care & Research · doi:10.1002/art.22094 · Cited by 184 · see citing works
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
Solomon, D. H., Avorn, J., Katz, J. N., Weinblatt, M. E., Setoguchi, S., Levin, R., & Schneeweiß, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22255 · Cited by 181 · see citing works
Self-citation
A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death
Fox, C. S., Evans, J. C., Larson, M. G., Lloyd‐Jones, D. M., O’Donnell, C. J., Sorlie, P. D., Manolio, T. A., Kannel, W. B., & Levy, D. A. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.12.011 · Cited by 75 · see citing works
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases
Weisman, M. H., Paulus, H. E., Burch, F. X., Kivitz, A., Fierer, J., Dunn, M. E., Kerr, D. R., Tsuji, W., & Baumgartner, S. W. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kem033 · Cited by 65 · see citing works
A computer case definition for sudden cardiac death
Chung, C. P., Murray, K. T., Stein, C. M., Hall, K., & Ray, W. A. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1888 · Cited by 51 · see citing works
An algorithm to identify incident myocardial infarction using Medicaid data
Choma, N. N., Griffin, M. R., Huang, R. L., Mitchel, E. F., Kaltenbach, L. A., Gideon, P. S., Stratton, S. M., & Roumie, C. L. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1821 · Cited by 46 · see citing works
Self-citation
Synthesis of TNFα and TGFβ mRNA in the different micro-environments within atheromatous plaques
Rayment, N. B., Moss, E., Faulkner, L., Brickell, P. M., DAVIES, M., Woolf, N., & Katz, D. R. (1996) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00145-9 · Cited by 38 · see citing works
Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics
Rassen, J. A., Solomon, D. H., Curtis, J. R., Herrinton, L. J., & Schneeweiß, S. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181d59541 · Cited by 37 · see citing works
Self-citation
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems
Herrinton, L. J., Curtis, J. R., Chen, L., Liu, L., Delzell, E., Lewis, J. D., Solomon, D. H., Griffin, M. R., Ouellet‐Hellstrom, R., Beukelman, T., et al. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2196 · Cited by 31 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690 · see citing works
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
Agca, R., Heslinga, S. C., Rollefstad, S., Heslinga, M., McInnes, I. B., Peters, M. J. L., Kvien, T. K., Dougados, M., Radner, H., Atzeni, F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209775 · Cited by 1,380 · see citing works
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206624 · Cited by 907 · see citing works
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
England, B. R., Thiele, G. M., Anderson, D. R., & Mikuls, T. R. (2018) · BMJ · doi:10.1136/bmj.k1036 · Cited by 627 · see citing works
Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions
Mason, J. C., & Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu403 · Cited by 420 · see citing works
Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke
Esenwa, C. C., & Elkind, M. S. V. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.125 · Cited by 282 · see citing works
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
Kim, S. C., Solomon, D. H., Rogers, J. R., Gale, S. L., Klearman, M., Sarsour, K., & Schneeweiß, S. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40084 · Cited by 196 · see citing works
Self-citation
Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer
Scott, F. I., Mamtani, R., Brensinger, C. M., Haynes, K., Fuxench, Z. C. C., Zhang, J., Chen, L., Xie, F., Yun, H., Osterman, M. T., et al. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.3029 · Cited by 183 · see citing works
Self-citation
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease
Weber, B., Giles, J. T., & Liao, K. P. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00969-7 · Cited by 175 · see citing works
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis
Singh, S., Fuméry, M., Singh, A. G., Singh, N., Prokop, L. J., Dulai, P. S., Sandborn, W. J., & Curtis, J. R. (2019) · Arthritis Care & Research · doi:10.1002/acr.23875 · Cited by 161 · see citing works
Self-citation
Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209784 · Cited by 158 · see citing works
Inflammation, Autoimmunity, Infection, and Stroke
Parikh, N. S., Merkler, A. E., & Iadecola, C. (2020) · Stroke · doi:10.1161/strokeaha.119.024157 · Cited by 151 · see citing works
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Lee, J. L., Sinnathurai, P., Buchbinder, R., Hill, C. L., Lassere, M. N., & MARCH, L. M. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1669-x · Cited by 123 · see citing works
The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Özen, G., Pedro, S., & Michaud, K. D. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200265 · Cited by 96 · see citing works
Dyslipidemia in rheumatoid arthritis: the possible mechanisms
Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Huang, Y., Huang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254753 · Cited by 91 · see citing works
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
Ljung, L., Rantapää‐Dahlqvist, S., Jacobsson, L., & Askling, J. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208995 · Cited by 86 · see citing works
Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022
Dijkshoorn, B., Raadsen, R., & Nurmohamed, M. T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102704 · Cited by 85 · see citing works
Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study
Kang, E. H., Jin, Y., Brill, G. E., Lewey, J., Patorno, E., Desai, R. J., & Kim, S. C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007393 · Cited by 80 · see citing works
Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High‐Risk Lesions
Karpouzas, G. A., Ormseth, S. R., Hernández, E., & Budoff, M. J. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41293 · Cited by 79 · see citing works
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study
Ljung, L., Askling, J., Rantapää‐Dahlqvist, S., Jacobsson, L., & for the ARTIS Study Group (2014) · Arthritis Research & Therapy · doi:10.1186/ar4584 · Cited by 77 · see citing works
Flexible two-layer dissolving and safing microneedle transdermal of neurotoxin: A biocomfortable attempt to treat Rheumatoid Arthritis
Yao, W., Tao, C., Zou, J., Zheng, H., Zhu, J., Zhu, Z., Zhu, J., Liu, L., Li, F., & Song, X. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.03.033 · Cited by 66 · see citing works
Self-citation
Dissolving microneedle patch-assisted transdermal delivery of methotrexate improve the therapeutic efficacy of rheumatoid arthritis
Zhao, W., Zheng, L., Yang, J., Ma, Z., Tao, X., & Wang, Q. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2157518 · Cited by 62 · see citing works
Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches
Chodara, A. M., Wattiaux, A., & Bartels, C. M. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0643-y · Cited by 62 · see citing works
Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis
Reverri, E. J., Morrissey, B. M., Cross, C. E., & Steinberg, F. M. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.005 · Cited by 60 · see citing works
The role of DNA damage and repair in atherosclerosis: A review
Shah, N. R., & Mahmoudi, M. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.07.005 · Cited by 55 · see citing works
Association between inflammatory markers and frailty in institutionalized older men
Lai, H., Chang, H., Lee, Y. L., & Hwang, S. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.07.014 · Cited by 54 · see citing works
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis
Cantini, F., Niccoli, L., Nannini, C., Cassarà, E. A. M., KALOUDI, O., Favalli, E. G., Becciolini, A., Biggioggero, M., Benucci, M., Gobbi, F. L., et al. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.10.001 · Cited by 53 · see citing works
Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy
Popescu, D., Rezuş, E., Bădescu, M. C., Dima, N., Isac, P. N. S., Dragoi, I.-T., & Rezuș, C. (2023) · Life · doi:10.3390/life13020319 · Cited by 50 · see citing works
Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort
Meißner, Y., Richter, A., Manger, B., Tony, H.-P., Wilden, E., Listing, J., Zink, A., & Strangfeld, A. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211209 · Cited by 47 · see citing works
Psoriasis comorbidities: complications and benefits of immunobiological treatment
de Carvalho, A. V. E., Santa Casa de Misericórdia de Porto Alegre, B., Romiti, R., Souza, C. D. S., Paschoal, R. S., Milman, L. D. M., MENEGHELLO, L. P., & B. (2016) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.20165080 · Cited by 46 · see citing works
Role of Inflammatory Cytokines in Rheumatoid Arthritis and Development of Atherosclerosis: A Review
Bedeković, D., Bošnjak, I., Šarić, S., Kirner, D., & Novak, S. (2023) · Medicina · doi:10.3390/medicina59091550 · Cited by 44 · see citing works
Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities
Arida, A., Protogerou, A. D., Konstantonis, G. D., Fragiadaki, K., Kitas, G. D., & Sfikakis, P. P. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kew506 · Cited by 40 · see citing works
Rheumatoid Arthritis — Anti-TNF
Chaabo, K., & Kirkham, B. W. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.04.051 · Cited by 38 · see citing works
Metabolic Abnormalities, Cardiovascular Disease, and Metabolic Syndrome in Adult Rheumatoid Arthritis Patients: Current Perspectives and Clinical Implications
Santos-Moreno, P., Rodríguez-Vargas, G.-S., Martínez, S., Ibatá, L., & Rojas‐Villarraga, A. (2022) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s285407 · Cited by 38 · see citing works
Epicardial Fat Thickness as Cardiovascular Risk Factor and Therapeutic Target in Patients with Rheumatoid Arthritis Treated with Biological and Nonbiological Therapies
Lima-Martínez, M. M., Campo, E., Salazar, J., Paoli, M., Maldonado, I., Acosta, C., Rodney, M., Contreras, M., Cabrera-Rego, J. O., & Iacobellis, G. (2014) · Arthritis · doi:10.1155/2014/782850 · Cited by 37 · see citing works
The 2013 ACC/AHA 10-year atherosclerotic cardiovascular disease risk index is better than SCORE and QRisk II in rheumatoid arthritis: is it enough?
Özen, G., Sünbül, M., Atagündüz, P., Di̇reskeneli̇, H., Tigen, K., & İnanç, N. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev363 · Cited by 34 · see citing works
Disease‐Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study
Desai, R. J., Eddings, W., Liao, K. P., Solomon, D. H., & Kim, S. C. (2014) · Arthritis Care & Research · doi:10.1002/acr.22483 · Cited by 34 · see citing works
Self-citation
Cardiovascular Disease in Rheumatoid Arthritis
Sen, D., González-Mayda, M., & Brasington, R. (2013) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2013.10.005 · Cited by 32 · see citing works
Effect of Treating Psoriasis on Cardiovascular Co-Morbidities: Focus on TNF Inhibitors
Famenini, S., Sako, E. Y., & Wu, J. J. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0052-6 · Cited by 31 · see citing works
Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study
Desai, R. J., Rao, J. K., Hansen, R. A., Fang, G., Maciejewski, M. L., & Farley, J. F. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131464 · Cited by 31 · see citing works
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis
Desai, R. J., Solomon, D. H., Schneeweiß, S., Danaei, G., Liao, K. P., & Kim, S. C. (2016) · Epidemiology · doi:10.1097/ede.0000000000000446 · Cited by 29 · see citing works
Self-citation
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors
Atzeni, F., Talotta, R., Nucera, V., Marino, F., Gerratana, E., Sangari, D., Masala, I. F., & Sarzi‐Puttini, P. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1504678 · Cited by 28 · see citing works
Effects of anti‐ TNF ‐α agents on circulating endothelial‐derived and platelet‐derived microparticles in psoriasis
Pelletier, F., Garnache‐Ottou, F., Biichlé, S., Vivot, A., Humbert, P. G., Saas, P., Seillès, E., & Aubin, F. (2014) · Experimental Dermatology · doi:10.1111/exd.12551 · Cited by 26 · see citing works
Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study
Curtis, J. R., Xie, F., Chen, L., Saag, K. G., Yun, H., & Muntner, P. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211727 · Cited by 26 · see citing works
Self-citation
Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
Nair, S., Kahlon, S. S., Sikandar, R., Peddemul, A., Tejovath, S., Hassan, D., Patel, K., & Mostafa, J. A. (2022) · Cureus · doi:10.7759/cureus.26430 · Cited by 28 · see citing works
Red Cell Distribution Width and Absolute Lymphocyte Count Associate With Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis
Lange, A., Kostadinova, L., Damjanovska, S., Gad, I., Syed, S., Siddiqui, H., Yousif, P. A., Kowal, C. M., Shive, C. L., Burant, C. J., et al. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.211411 · Cited by 26 · see citing works
Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies
Boyce, E. G., Vyas, D., Rogan, E. L., Valle-Oseguera, C. S., & O’Dell, K. M. (2016) · Patient Related Outcome Measures · doi:10.2147/prom.s62879 · Cited by 26 · see citing works
Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
Kang, E. H., Liao, K. P., & Kim, S. C. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0752-2 · Cited by 25 · see citing works
Role of A20 in cIAP-2 Protection against Tumor Necrosis Factor α (TNF-α)-Mediated Apoptosis in Endothelial Cells
Guo, S., Messmer-Blust, A. F., Wu, J., Song, X., Philbrick, M. J., Shie, J., Rana, J. S., & Li, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033816 · Cited by 25 · see citing works
Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China
Li, C., Wang, X., Ji, H., Zhang, X. Y., Li, X. F., Wang, L. Z., Wang, C., Wang, Y.-F., Yang, R., Wang, G. C., et al. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3596-7 · Cited by 24 · see citing works
Self-citation
Antiarthritic Activity of Qi‐Wu Rheumatism Granule (a Chinese Herbal Compound) on Complete Freund’s Adjuvant‐Induced Arthritis in Rats
Xu, Q., Zhou, Y., Zhang, R., Sun, Z., & Cheng, L.-F. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/1960517 · Cited by 24 · see citing works
Retracted
Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
Day, A. L., & Singh, J. A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00653-0 · Cited by 24 · see citing works
Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis
Tocci, G., Goletti, D., Marino, V., Matucci, A., Milano, G. M., Cantini, F., & Scarpa, R. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1218469 · Cited by 23 · see citing works
Prevention of Stroke in Rheumatoid Arthritis
Zha, A. M., Napoli, M. D., & Behrouz, R. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0600-y · Cited by 22 · see citing works
Cytoprotective pathways in the vascular endothelium. Do they represent a viable therapeutic target?
Mason, J. C. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.08.002 · Cited by 22 · see citing works
Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights
Karpouzas, G. A., Bui, V. L., Ronda, N., Hollan, I., & Ormseth, S. R. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1899809 · Cited by 23 · see citing works
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
Delcoigne, B., Ljung, L., Provan, S. A., Glintborg, B., Hetland, M. L., Grøn, K. L., Peltomaa, R., Relas, H., Turesson, C., Guðbjörnsson, B., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221996 · Cited by 20 · see citing works
Prevention of Stroke in Rheumatoid Arthritis
Dhillon, N., & Liang, K. P. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0356-3 · Cited by 20 · see citing works
Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis
Galajda, N. Á., Meznerics, F. A., Mátrai, P., Fehérvári, P., Lengyel, A., Kolonics, M. V., Sipos, Z., Kemény, L. V., Csupor, D., Hegyi, P. J., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19900 · Cited by 20 · see citing works
Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study
Weber, B., Weisenfeld, D., Massarotti, E. M., Seyok, T., Cremone, G., Lam, E., Golnik, C., Brownmiller, S., Liu, F., Huang, S., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030387 · Cited by 17 · see citing works
Self-citation
Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin‐6 receptor‐alpha inhibition with tocilizumab
Lee, J. S., Chapman, M. J., Piraino, P., Lamerz, J., Schindler, T. H., Cutler, P., & Dernick, G. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500036 · Cited by 17 · see citing works
Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis
Luciano, N., Barone, E., Timilsina, S., Gershwin, M. E., & Selmi, C. F. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08975-z · Cited by 16 · see citing works
Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan
Chen, D.-Y., Yu, F., Tuan, L.-W., & Tang, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01214 · Cited by 16 · see citing works
Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review
Daniel, C., Davila, L., Makris, U. E., Mayo, H., Caplan, L., Davis, L. A., & Solow, E. B. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11170 · Cited by 16 · see citing works
Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population‐based cohort study in Taiwan
Tang, C., Yu, F., Huang, C., & Chen, D. (2019) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13611 · Cited by 16 · see citing works
An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score
Desai, R. J., Solomon, D. H., Weinblatt, M. E., Shadick, N. A., & Kim, S. C. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0599-0 · Cited by 14 · see citing works
Self-citation
Low Levels of CD36 in Peripheral Blood Monocytes in Subclinical Atherosclerosis in Rheumatoid Arthritis: A Cross-Sectional Study in a Mexican Population
Gómez-Bañuelos, E., Martín-Márquez, B. T., Martínez-García, E. A., Figueroa-Sanchez, M., Núñez-Atahualpa, L., Rocha-Muñoz, A. D., Sánchez‐Hernández, P. E., Navarro-Hernández, R. E., Madrigal-Ruiz, P. M., Saldaña-Millan, A., et al. (2014) · BioMed Research International · doi:10.1155/2014/736786 · Cited by 14 · see citing works
Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis
Myasoedova, E., & Matteson, E. L. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001007 · Cited by 12 · see citing works
The Effect of TNF-α on CHD and the Relationship between TNF-α Antagonist and CHD in Rheumatoid Arthritis: A Systematic Review
Qian, Y., Mao, M., & Nian, F. (2022) · Cardiology Research and Practice · doi:10.1155/2022/6192053 · Cited by 14 · see citing works
Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study
Yamada, Z., Muraoka, S., Kawazoe, M., Hirose, W., Kono, H., Yasuda, S., Sugihara, T., & Nanki, T. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03323-8 · Cited by 11 · see citing works
Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?
Soh, M. C., Nelson‐Piercy, C., Westgren, M., McCowan, L. M. E., & Pasupathy, D. (2017) · Lupus · doi:10.1177/0961203317719146 · Cited by 11 · see citing works
The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients
Almutairi, K. B., Nossent, J. C., Preen, D. B., Keen, H. I., & Inderjeeth, C. A. (2021) · Rheumatology International · doi:10.1007/s00296-021-04985-2 · Cited by 11 · see citing works
Managing premature atherosclerosis in patients with chronic inflammatory diseases
Legge, A. C., & Hanly, J. G. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170776 · Cited by 9 · see citing works
Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients
Pappas, D. A., Reed, G. W., Kane, K., Curtis, J. R., Charles‐Schoeman, C., Giles, J. T., & Kremer, J. M. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152504 · Cited by 8 · see citing works
Self-citation
Progression of subclinical atherosclerosis in ankylosing spondylitis: a 10-year prospective study
Arida, A., Fragoulis, G. E., Terentes-Printzios, D. G., Konstantonis, G. D., Protogerou, A. D., Vlachopoulos, C. V., Tektonidou, M. G., & Sfikakis, P. P. (2024) · Rheumatology International · doi:10.1007/s00296-023-05528-7 · Cited by 7 · see citing works
Risk of acute myocardial infarction associated with antirheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study
Ahn, S. M., Kim, S., Kim, Y., Hong, S., Lee, C., Yoo, B., Oh, J. S., & Kim, Y. (2024) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2024.0104 · Cited by 7 · see citing works
Gel based on cubic liquid crystals nanoparticles enhance anti-inflammation and bone protection effects of triptolide
Pei, W.-J., Wu, Y.-Z., Wang, Y., Ding, Q., Guo, X., Ren, F.-L., & Wang, X. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103387 · Cited by 7 · see citing works
Future of Uremic Toxin Management
Vanholder, R. C., Snauwaert, E., Verbeke, F., & Glorieux, G. (2024) · Toxins · doi:10.3390/toxins16110463 · Cited by 6 · see citing works
Investigating the Mechanisms of Action of Depside Salt from Salvia miltiorrhiza Using Bioinformatic Analysis
Li, H., & Liu, H. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/5671860 · Cited by 6 · see citing works
Exploring the Subclinical Atherosclerotic Load in Patients With Rheumatoid Arthritis: A Cross-Sectional Study
Arora, A., Ingle, V., Joshi, R. P., Malik, R. K., & Khandelwal, G. (2022) · Cureus · doi:10.7759/cureus.32644 · Cited by 6 · see citing works
Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis?
Purcărea, A., Sovaila, S., Gheorghe, A., Udrea, G., & Stoica, V. (2014) · Europe PMC (PubMed Central) · Cited by 6 · see citing works
Effect of ethanol extract of Punica granatum L against Freund’s complete adjuvant-induced arthritis in rats
Wang, Y., He, T., Li, Z., & Gai, S. (2021) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v18i3.21 · Cited by 6 · see citing works
Therapie kardiovaskulärer Risikofaktoren
Krüger, K. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0064-8 · Cited by 5 · see citing works
Use of large healthcare databases for rheumatology clinical research
Desai, R. J., & Solomon, D. H. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000363 · Cited by 5 · see citing works
Self-citation
Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis – why cardiovascular risk factors do not equate to overt risk
Felis‐Giemza, A., Moskal, M., Proc, K., Guzera, Z., Stajszczyk, M., Palej, K., Chmurzyńska, K., Wiland, P., Batko, K., & Batko, B. P. (2024) · Reumatologia/Rheumatology · doi:10.5114/reum/175626 · Cited by 4 · see citing works
An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches
Herrinton, L. J., Ray, G. T., Curtis, J. R., Wu, J. J., FIREMAN, B. H., Liu, L., & Goldfien, R. D. (2018) · The Permanente Journal · doi:10.7812/tpp/17-101 · Cited by 4 · see citing works
Self-citation
The Influence of Rheumatoid Arthritis and Osteoarthritis on the Occurrence of Arterial Hypertension: An 8-Year Prospective Clinical Observational Cohort Study
Bedeković, D., Kirner, D., Bošnjak, I., Kibel, A., Šarić, S., Novak, S., & Prus, V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12227158 · Cited by 3 · see citing works
Factors associated with secondary coronary artery disease in rheumatoid arthritis patients: A systematic review and meta‐analysis based on observational studies
Wang, Z., Hu, K., Wu, M., Feng, L., Liu, C., Ding, F., Li, X., & Ma, B. (2023) · Musculoskeletal Care · doi:10.1002/msc.1850 · Cited by 3 · see citing works
Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study
Huang, Y., Agarwal, S. K., Chatterjee, S., Chen, H., Johnson, M. L., & Aparasu, R. R. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06709-2 · Cited by 3 · see citing works
Comorbidities in Patients With Rheumatic Disease
Radner, H. (2018) · Technical report · doi:10.1016/b978-0-444-63887-8.00002-5 · Cited by 2 · see citing works
Calcium Complexes of Oxicams: New Dimensions in Rheumatoid Arthritis Treatment
Sadia, A., Yasmin, T., Imran, M., Samra, M. M., & Basra, M. A. R. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0032 · Cited by 2 · see citing works
Rapid crystal dissolution in gout: is it feasible and advisable?
Andrés, M., Sivera, F., & Pascual, E. (2014) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.14.28 · Cited by 2 · see citing works
Algorithm for Selecting Ideal Biologic Treatment for Psoriasis
Asahina, Y. U. A., Kikuchi, S., & Nakagawa, H. (2015) · Journal of Clinical & Experimental Dermatology Research · doi:10.4172/2155-9554.1000297 · Cited by 2 · see citing works
EVALUATION OF EPICARDIAL FAT THICKNESS, A NEW INDICATOR OF THE CARDIOVASCULAR RISK FACTOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Hakbilen, S., Yılmaz, S., Özer, H., Topoloğlu, Ö. F., Kılınçer, A., Tezcan, D., & Körez, M. K. (2023) · Rheumatology Quarterly · doi:10.4274/qrheumatol.galenos.2023.68552 · Cited by 1 · see citing works
Beyond skin: Integrating the cardiovascular impact of psoriasis therapies into disease management
Torres, T. R. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20828 · Cited by 1 · see citing works
Cardiovascular risks and primary interventions among treated rheumatoid arthritis patients: Experience from a tertiary care centre in Kuala Lumpur, Malaysia
Radhakrishnan, S., Razak, S. A., Said, M. S. M., Shah, N. M., & Redzuan, A. M. (2022) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v21i4.25 · Cited by 1 · see citing works
Antibodies against biologicals and acute coronary syndromes
Gori, T., & Münzel, T. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.012 · Cited by 1 · see citing works
Rheumatoid arthritis and cardiac disease
González-Mayda, M., Sen, D., & Brasington, R. (2014) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.14.40
TNF-α inhibitors and tocilizumab do not influence hepatic steatosis in patients with rheumatoid arthritis
Sessa, P. (2014) · World Journal of Rheumatology · doi:10.5499/wjr.v4.i1.1
Improving the measurement and detection of serious adverse drug reactions in databases of stored electronic health records
Wing, K. (2016) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.02545199

FRI0142 TNF-blocking therapy reduces cardiovascular disease and risk factors in rheumatoid arthritis
van Sijl, A. M., Visman, I. M., Peters, M. J. L., van Dongen, C. J. J., Smulders, Y. M., Voskuyl, A. E., & Nurmohamed, M. T. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-eular.2599 · Cited by 1 · see citing works
TNF-α inhibitor treatment and the risk of cardiovascular events in patients newly diagnosed with rheumatoid arthritis
Desai, R. J. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/1mw4-g818
Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study
Desai, R. J., Rao, J. K., Hansen, R. A., Fang, G., Maciejewski, M. L., & Farley, J. F. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131464 · Cited by 31 · see citing works
Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
Nair, S., Kahlon, S. S., Sikandar, R., Peddemul, A., Tejovath, S., Hassan, D., Patel, K., & Mostafa, J. A. (2022) · Cureus · doi:10.7759/cureus.26430 · Cited by 28 · see citing works
Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis
Luciano, N., Barone, E., Timilsina, S., Gershwin, M. E., & Selmi, C. F. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08975-z · Cited by 16 · see citing works

Authors: Solomon, D. H., Curtis, J. R., Saag, K. G., Lii, J., Chen, L., Harrold, L. R., Herrinton, L. J., Graham, D. J., Kowal, M. K., Kuriya, B., Liu, L., Griffin, M. R., Lewis, J. D., & Rassen, J. A.
Affiliations: Brigham and Women's Hospital (US)
University of Alabama at Birmingham (US)
University of Massachusetts Chan Medical School (US)
Kaiser Permanente (US)
United States Food and Drug Administration (US)
University of Toronto (CA)
Vanderbilt University (US)
University of Pennsylvania (US)
Corresponding author: Solomon, Daniel H.
ORCID: Solomon, Daniel H.
Curtis, Jeffrey R.
Saag, Kenneth G.
Harrold, Leslie R.
Herrinton, Lisa J.
Graham, David J.
Kuriya, Bindee
Liu, Liyan
Griffin, Marie R.
Lewis, James D.
Rassen, Jeremy A.
Venue: The American Journal of Medicine
Publisher: Elsevier BV
Published: 2013-08
Volume: 126
Issue: 8
Pages: 730.e9-730.e17
ISSN: 0002-9343 (ISSN-L)
DOI: 10.1016/j.amjmed.2013.02.016
PMC: PMC4674813
OpenAlex: W1995953874
Cited by: 111
References: 42
Citations by year: 2026: 1 · 2025: 1 · 2024: 11 · 2023: 10 · 2022: 11 · 2021: 3 · 2020: 6 · 2019: 5 · 2018: 10 · 2017: 12 · 2016: 11 · 2015: 12 · 2014: 14 · 2013: 4
FWCI: 11.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The American Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Food and Drug Administration
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services (1U18 HSO17919-0)
Topics: Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
Keywords: rheumatoid arthritis, cardiovascular risk, TNF-alpha blockade, methotrexate, myocardial infarction, stroke, coronary revascularization, cardiovascular events, older adults, propensity score matching
MeSH terms: Adult, Aged, Arthritis, Rheumatoid, Cardiovascular Diseases, Female, Humans, Male, Methotrexate, Middle Aged, Myocardial Infarction, Myocardial Revascularization, Retrospective Studies, Risk, Tumor Necrosis Factor-alpha, Cohort Studies, Proportional Hazards Models, Treatment Outcome, Antirheumatic Agents, Stroke, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks